Company intelligence / Profile preview
EnteroBiotix
Glasgow, Scotland, United Kingdomenterobiotix.com ↗
- Ownership
- Private
- Employees
- ~53
- Development stage
- Phase 2
01
Overview
EnteroBiotix has reported promising safety and efficacy data from a completed Phase Ib study in liver cirrhosis, showing improvements in gut barrier function and patient-reported outcomes. Interim analysis from a Phase II IBS-C cohort has generated positive efficacy signals. Ongoing partnered trials include a Phase IIa study with Imperial College London targeting Allo-HSCT patients.
- Therapeutic areas
- GastroenterologyHematology
- Modalities
- Full-spectrum microbial therapeutics (microbiome-based therapies)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Imperial College London – partnered clinical trial(s) in Allo-HSCT patients.Functional Gut Clinic – partnership for IBS clinical trial.
Beyond the preview
Go deeper on EnteroBiotix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EnteroBiotix.